Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.271
Sell
RSI(14)
45.383
Neutral
STOCH(KDJ)(9,3,3)
25.737
Neutral
ATR(14)
0.695
High Vlolatility
CCI(14)
-51.162
Neutral
Williams %R
72.653
Sell
TRIX(12,20)
-0.217
Sell
StochRSI(14)
86.112
Buy
Zai Lab Ltd
ZLAB18.000USD
+0.490+2.80%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
1.99BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Zai Lab Ltd
Currency: USD Updated: 2026-03-27Key Insights
Zai Lab Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 72 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 36.11.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zai Lab Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Zai Lab Ltd Highlights
StrengthsRisks
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 72.52% year-on-year.
Undervalued
The company’s latest PE is -11.23, at a low 3-year percentile range.
Held by Sarah Ketterer
Star Investor Sarah Ketterer holds 50.91K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.33.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
36.113
Target Price
+106.71%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Zai Lab Ltd is 7.91, ranking 79 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 127.60M, representing a year-over-year increase of 16.99%, while its net profit experienced a year-over-year increase of 38.29%.
Score
Financials
8.33
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.26
Operational Efficiency
9.19
Growth Potential
7.52
Shareholder Returns
7.25
Zai Lab Ltd's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Zai Lab Ltd is 7.41, ranking 70 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -11.23, which is -65.11% below the recent high of -3.92 and -76.22% above the recent low of -19.79.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 72/157
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Zai Lab Ltd is 8.33, ranking 41 out of 157 in the Pharmaceuticals industry. The average price target is 48.00, with a high of 67.22 and a low of 23.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
36.113
Target Price
+106.71%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Zai Lab Ltd
ZLAB
12
Biogen Inc
BIIB
37
Amgen Inc
AMGN
36
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
32
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Zai Lab Ltd is 6.47, ranking 109 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 19.49 and the support level at 16.81, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
17.776
Buy
MA10
18.249
Sell
MA20
18.581
Sell
MA50
18.550
Sell
MA100
19.102
Sell
MA200
26.434
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Zai Lab Ltd is 3.00, ranking 93 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 42.38%, representing a quarter-over-quarter increase of 6.36%. The largest institutional shareholder is Ron Baron, holding a total of 1.42M shares, representing 1.26% of shares outstanding, with 24.19% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
RTW Investments L.P.
Frazier Life Sciences Management, L.P.
ClearBridge Investments, LLC
Citadel Advisors LLC
Fidelity Management & Research Company LLC
Adar1 Capital Management LLC
Du (Ying Samantha)
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Zai Lab Ltd is 5.28, ranking 70 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.89. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.89
VaR
+6.90%
240-Day Maximum Drawdown
+62.12%
240-Day Volatility
+56.57%
Return
Best Daily Return
60 days
+8.75%
120 days
+8.75%
5 years
+41.80%
Worst Daily Return
60 days
-4.26%
120 days
-7.52%
5 years
-20.31%
Sharpe Ratio
60 days
+0.31
120 days
-2.71
5 years
-0.23
Risk Assessment
Maximum Drawdown
240 days
+62.12%
3 years
+62.12%
5 years
+92.31%
Return-to-Drawdown Ratio
240 days
-0.63
3 years
-0.25
5 years
-0.19
Skewness
240 days
+1.21
3 years
+0.82
5 years
+1.13
Volatility
Realised Volatility
240 days
+56.57%
5 years
+77.44%
Standardised True Range
240 days
+6.89%
5 years
+13.73%
Downside Risk-Adjusted Return
120 days
-466.78%
240 days
-466.78%
Maximum Daily Upside Volatility
60 days
+47.74%
Maximum Daily Downside Volatility
60 days
+41.70%
Liquidity
Average Turnover Rate
60 days
+0.07%
120 days
+0.09%
5 years
--
Turnover Deviation
20 days
-33.12%
60 days
-4.22%
120 days
+18.93%
Peer Comparison
Pharmaceuticals
Zai Lab Ltd
ZLAB
6.88 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Innoviva Inc
INVA
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
